In the latest twist in the generic drug industry’s mega-merger saga, Mylan on Monday formally rejected Teva Pharmaceutical Industries’ unsolicited roughly $43 billion takeover proposal, saying the offer “grossly undervalues” the company and would expose Mylan shareholders “to a problematic culture and leadership.”

“We do not wish to make Teva’s problems Mylan’s problems, or to inflict them on Mylan’s shareholders and other stakeholders,” Mylan chairman Robert Coury wrote in a blistering and lengthy letter to Teva CEO Erez Vigodman, calling Israel-based Teva a “poorly performing troubled company.”

The letter was the clearest statement yet that Mylan’s board and management — which run the Netherlands-based company from its operational headquarters in Cecil — intends to keep Mylan independent with current management in place. The rejection wasn’t a surprise given Mylan’s earlier statements that it wasn’t interested in hooking up with Teva.

Teva quickly issued a news release Monday saying it was disappointed at the response but undaunted in its effort to join the two generic drug giants.

Advertise with us

“The Teva board and management team are fully committed to completing the combination of Teva and Mylan,” Mr. Vigodman said.

“Teva stands ready and willing to meet with Mylan and its advisors immediately” to work out a deal, Teva’s statement said. “Teva is offering [Mylan shareholders] a substantial premium … and the opportunity to participate in the significant upside potential of a financially and commercially stronger company.”

Teva’s bid to acquire Mylan for $82 per share in cash and stock was made last week in the midst of Mylan’s quest to acquire Irish over-the-counter drug specialist Perrigo, announced earlier in the month.

Mylan’s sweetened offer for Perrigo — valued at about $31 billion in cash and stock, and made three days after Teva entered the fray — was rejected as inadequate and inferior to Mylan’s initial offer. Mylan’s bid for Perrigo had been widely viewed as a pre-emptive maneuver to fend off advances from Teva.

News that Mylan had rejected Teva’s offer on Monday sent Mylan shares sharply lower. Shares lost $4.34, or 5.71 percent, to close at $71.72. Shares of Teva fell $2.78, or 4.32 percent, to finish at $61.63, while Perrigo gave up $4.61, or 2.39 percent, to $188.28.

Advertise with us

The latest sparring set up the possibly of a protracted battle between Teva, the world’s biggest generic drug company, and No. 3 Mylan as analysts speculated on what would happen next.

Canaccord Genuity analyst Corey Davis said in an email that Teva’s best strategy would be to appeal directly to Mylan shareholders to get them to put pressure on the board to engage Teva.

“The next step is for Teva to plead its case to investors, but it’ll probably take a raise of its $82 offer before anything can materialize,” Mr. Davis said.

Bloomberg News said it had polled five unnamed investors who said a suitable price for Mylan would be $85 to $95 a share.

Talk began to swirl Monday that Teva had begun to lobby Mylan’s key shareholders to win their support. That support is crucial, analysts said, because Mylan has put in place a so-called poison pill anti-takeover defense aimed at making a hostile bid prohibitively expensive.

Advertise with us

Mylan’s largest shareholders include Abbott Laboratories (which acquired its stake earlier this year when it sold a major chunk of its non-U.S. operations to Mylan), Blackrock and Vanguard Group, which together hold about one-quarter of the generic drugmaker’s shares.

Mr. Davis said Mylan won’t be able to persuade Perrigo to accept an offer as long as the Teva bid is on the table. “Mylan can’t buy Perrigo with an artificially high stock price” that has been pushed up by Teva’s offer, he said. “In order to make Perrigo happen, Mylan needs to get Teva to withdraw its offer to allow its stock to settle back into the unaffected range.”

Some observers speculated it would be easier for Teva to raise its bid for Mylan than for Mylan to increase its offer substantially for Perrigo because of the higher cost-savings that Teva is projecting by combining with Mylan.

In his letter to Teva, Mr. Coury said the starting point for any discussions about acquiring Mylan would have to be “significantly in excess of $100 per share.” He also said an acquirer would have to be the right “cultural fit,” which he said Teva was not.

“To be frank, given Teva’s history and actions to date, it is implausible that Teva can realistically satisfy our minimum criteria,” he said.

Advertise with us

Among other things, he criticized Teva for going public with its proposal without first approaching him privately. He also reiterated that Teva’s bid would likely be rebuffed by regulators because of antitrust concerns.

In response, Teva repeated that it was confident of making the necessary divestitures to gain regulatory approval and that it had begun the process of obtaining regulatory clearances for the proposed combination.

Mr. Coury also took aim at Teva’s board, saying it “lacks adequate global pharmaceutical experience” and “consistently meddles in company operations,” which he said has created Teva’s “challenged culture.”

“Since 2007, your board has churned through three different chief executive officers, running the only one with the global pharmaceutical experience, which we think is critical to the position, out of town within 18 months of being on the job,” leaving the company with “a complete lack of long-term strategic focus,” Mr. Coury said.